C H Polman

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
    Chris H Polman
    Department of Neurology, MS Center Amsterdam, Free University Medical Center, Amsterdam, Netherlands
    Lancet Neurol 9:740-50. 2010
  2. pmc A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility
    W S Bush
    Department of Molecular Physiology and Biophysics, Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37232 0700, USA
    Genes Immun 12:335-40. 2011
  3. pmc Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial
    Rosa E Boeschoten
    Department of Psychiatry, VU University Medical Center Academic Anxiety Outpatient Clinic and GGZinGeest, A J Ernststraat 1187, Amsterdam, HL 1081, The Netherlands
    BMC Psychiatry 12:137. 2012
  4. pmc Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data
    Joanne H Wang
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0435, USA
    Genome Med 3:3. 2011
  5. pmc Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years
    Femke A H van der Linden
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    BMC Neurol 8:2. 2008
  6. pmc The size of the treatment effect: do patients and proxies agree?
    Femke A H van der Linden
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    BMC Neurol 9:12. 2009
  7. pmc MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
    Jessica M Nielsen
    MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    BMC Neurol 9:19. 2009
  8. ncbi request reprint Multiple sclerosis diagnostic criteria: three years later
    Chris H Polman
    Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
    Mult Scler 11:5-12. 2005
  9. ncbi request reprint Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b
    C Polman
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Neurology 60:37-43. 2003
  10. ncbi request reprint Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
    C Polman
    Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
    Neurology 64:987-91. 2005

Collaborators

Detail Information

Publications161 found, 100 shown here

  1. doi request reprint Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis
    Chris H Polman
    Department of Neurology, MS Center Amsterdam, Free University Medical Center, Amsterdam, Netherlands
    Lancet Neurol 9:740-50. 2010
    ..In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity...
  2. pmc A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility
    W S Bush
    Department of Molecular Physiology and Biophysics, Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37232 0700, USA
    Genes Immun 12:335-40. 2011
    ..Further, the implicated genes cluster within inter-related biological mechanisms that suggest a neurodegenerative component to MS...
  3. pmc Internet-based self-help treatment for depression in multiple sclerosis: study protocol of a randomized controlled trial
    Rosa E Boeschoten
    Department of Psychiatry, VU University Medical Center Academic Anxiety Outpatient Clinic and GGZinGeest, A J Ernststraat 1187, Amsterdam, HL 1081, The Netherlands
    BMC Psychiatry 12:137. 2012
    ..An important underlying factor may be physical limitations that preclude face-to-face contact. Internet-based treatment showed to be effective for depressive symptoms in general and could thus be a promising tool for treatment in MS...
  4. pmc Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data
    Joanne H Wang
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0435, USA
    Genome Med 3:3. 2011
    ..Nevertheless, the knowledge of MS genetics remains incomplete, with many risk alleles still to be revealed...
  5. pmc Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years
    Femke A H van der Linden
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    BMC Neurol 8:2. 2008
    ..g. partners) may replace self-ratings. The aim of this study was to examine the value of proxy ratings at separate points in time and to assess patient-proxy agreement on possible changes in disease impact of MS...
  6. pmc The size of the treatment effect: do patients and proxies agree?
    Femke A H van der Linden
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    BMC Neurol 9:12. 2009
    ..This may be of interest in situations when patients suffer from limitations that interfere with reliable self-assessment, such as cognitive impairment...
  7. pmc MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
    Jessica M Nielsen
    MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    BMC Neurol 9:19. 2009
    ..Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS)...
  8. ncbi request reprint Multiple sclerosis diagnostic criteria: three years later
    Chris H Polman
    Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
    Mult Scler 11:5-12. 2005
    ....
  9. ncbi request reprint Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b
    C Polman
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Neurology 60:37-43. 2003
    ..To investigate the relationship between neutralizing antibodies (NAB) and disease progression, relapses, and MR measures of MS...
  10. ncbi request reprint Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
    C Polman
    Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
    Neurology 64:987-91. 2005
    ..The purpose of this study was to evaluate safety, tolerability, and efficacy on MRI lesions of two different doses of laquinimod compared with placebo in patients with relapsing MS...
  11. ncbi request reprint Interferon beta-1b treatment does not induce autoantibodies
    C H Polman
    Department of Neurology, Free University Hospital, Amsterdam, The Netherlands
    Neurology 64:996-1000. 2005
    ..Existing data from uncontrolled studies are contradictory and do not differentiate between autoimmune dysfunction, which is frequent in patients with multiple sclerosis (MS), and untoward drug effects...
  12. doi request reprint Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment
    C H Polman
    Department of Neurology, Free University Medical Center in Amsterdam, PO Box 4075, 1007 MB Amsterdam, The Netherlands
    Neurology 70:1134-40. 2008
    ..Guidance is also provided on the ethics of alternative trial designs and the balance between study subject burden and risk, scientific rationale and interpretability of trial outcomes...
  13. pmc Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
    Chris H Polman
    Department of Neurology, Free University, Amsterdam, The Netherlands
    Ann Neurol 69:292-302. 2011
    ..These revisions simplify the Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use...
  14. ncbi request reprint Statins for the treatment of multiple sclerosis: cautious hope
    Chris H Polman
    VU Medical Centre Amsterdam, 1007 MB Amsterdam, Netherlands
    Lancet 363:1570. 2004
  15. ncbi request reprint A rare, treatable cause of relapsing encephalopathy in an MS patient on interferon beta therapy
    Chris H Polman
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Neurology 61:719. 2003
  16. ncbi request reprint New and emerging treatment options for multiple sclerosis
    Chris H Polman
    Department of Neurology, VU Medical Center, Amsterdam, Netherlands
    Lancet Neurol 2:563-6. 2003
    ..In addition, these compounds reduce the development of new lesions, as detected by MRI...
  17. ncbi request reprint A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
  18. ncbi request reprint Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"
    Chris H Polman
    VU Medical Center Amsterdam, Free University, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Ann Neurol 58:840-6. 2005
    ..The 2005 Revisions to the McDonald Diagnostic Criteria for MS should simplify and speed diagnosis, whereas maintaining adequate sensitivity and specificity...
  19. ncbi request reprint Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b
    Chris Polman
    Vrije Universiteit Medical Centre, Amsterdam, The Netherlands
    J Neurol 255:480-7. 2008
    ..The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions...
  20. ncbi request reprint Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study
    C Polman
    Department of Neurology, Free University Medical Center, De Boelelaan 1117, NL 1007 MB Amsterdam, The Netherlands
    Mult Scler 9:342-8. 2003
    ..The purpose of this study was to evaluate safety, tolerability and effects on MRI lesions of three different doses of oral IFNB-1a compared with placebo over six months in relapsing-remitting (RR) MS patients...
  21. doi request reprint The multiple sclerosis functional composite: a clinically meaningful measure of disability
    Chris H Polman
    Department of Neurology, VU Medical Centre, Free University Hospital, PO Box 7057, Amsterdam, 1007 MB, The Netherlands
    Neurology 74:S8-15. 2010
    ....
  22. ncbi request reprint Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis
    M A van Walderveen
    Magnetic Resonance Center for Multiple Sclerosis Research, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Arch Neurol 58:76-81. 2001
    ..Clinical determinants of T1 lesions may differ between subgroups of patients with MS and subsequently may have implications for the selection of patients for clinical trials...
  23. doi request reprint Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS
    L F van der Voort
    VU Medical Center, Department of Neurology, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Neurology 75:1228-33. 2010
    ..To determine if myxovirus resistance protein A (MxA) mRNA is related to clinical disease activity in multiple sclerosis (MS)...
  24. ncbi request reprint Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease
    J Killestein
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 7:145-50. 2001
    ....
  25. ncbi request reprint Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters
    A Minneboo
    MS Center of the VU University Medical Center, Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 79:917-23. 2008
    ..The aim of this study was to investigate whether adding MRI parameters to a model with only clinical parameters could improve these associations...
  26. doi request reprint Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
    L V A E Bosma
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 16:862-7. 2010
    ..g. 15%) and is therefore preferable for the assessment of disease progression. No satisfactory cut-off point for the PASAT could be determined...
  27. ncbi request reprint [Alpha]B-crystallin genotype has impact on the multiple sclerosis phenotype
    T van Veen
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurology 61:1245-9. 2003
    ..Alpha]B-crystallin is a candidate autoantigen in MS, and there are three polymorphisms in the promoter region of the encoding gene (CRYAB): at positions -C249G, -C650G, and -A652G...
  28. doi request reprint Association between MRI parameters and the MS severity scale: a 12 year follow-up study
    A Minneboo
    Department of Radiology, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 15:632-7. 2009
    ..Until now, these studies are relatively sparse and, therefore, the predictive value of MRI parameters for clinical disability remains largely unknown...
  29. ncbi request reprint Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells
    J Killestein
    Department of Immunobiology, CLB and Laboratory of Experimental and Clinical Immunology of the University of Amsterdam, Amsterdam, The Netherlands
    J Neuroimmunol 118:286-94. 2001
    ..However, the exact mechanisms by which T cells and cytokines contribute to disease activity remain to be clarified...
  30. ncbi request reprint Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients
    M M Vellinga
    Department of Neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Neurology 70:1150-1. 2008
  31. ncbi request reprint Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis
    J Killestein
    Department of Neurology, VU Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    J Neuroimmunol 137:140-3. 2003
    ..In the subgroup of patients with high adverse event scores, we found an increase in plasma IL-12p40 (p=0.002). The results suggest pro-inflammatory disease-modifying potential of cannabinoids in MS...
  32. ncbi request reprint Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis
    H M Schrijver
    Department of Neurology, University Medical Center Utrecht, The Netherlands
    Eur J Immunogenet 31:133-40. 2004
    ..The IFNGR1 and IFNGR2 gene polymorphisms studied do not exert an important influence on MS susceptibility, but allele IFNGR2*Arg64 may be associated with a progressive disease onset...
  33. ncbi request reprint Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy
    M J Eikelenboom
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Neurology 60:219-23. 2003
    ..To evaluate markers of axonal damage in CSF and serum of patients with different subtypes of MS in relation to measures of disease progression on MRI...
  34. doi request reprint Disease progression in multiple sclerosis: combining physicians' and patients' perspectives?
    J J Kragt
    Department of Neurology, VU University Medical Center, The Netherlands
    Mult Scler 17:234-40. 2011
    ..The interrelation of changes on different scales has not been studied extensively and the concept of combining scales has only recently been introduced in MS...
  35. doi request reprint Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?
    T Korteweg
    Department of Radiology, VU University Medical Centre, Amsterdam, The Netherlands
    Mult Scler 15:465-71. 2009
    ..Multiple sclerosis (MS) is characterized, besides focal lesions, by brain atrophy. The determinants of atrophy rates in individual patients are poorly understood...
  36. doi request reprint Responsiveness and predictive value of EDSS and MSFC in primary progressive MS
    J J Kragt
    VU University Medical Center, Department of Neurology, De Boelelaan 1117, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Neurology 70:1084-91. 2008
    ..Disease course in PPMS shows less fluctuation than in relapsing remitting (RR) MS...
  37. doi request reprint Clinical correlations of brain lesion distribution in multiple sclerosis
    M M Vellinga
    Department of Neurology, MS Center Amsterdam, Amsterdam, The Netherlands
    J Magn Reson Imaging 29:768-73. 2009
    ..Hypothesizing that symptomatology may partly be determined by lesion location, this retrospective study explored relations between lesion location and disability using voxelwise analyses in standard space...
  38. ncbi request reprint Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS
    L M L van Winsen
    Department of Neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    J Neuroimmunol 186:150-5. 2007
    ..We investigated the influence of these polymorphisms on clinical and MRI parameters. The ER22/23EK polymorphism was associated with a more aggressive MS phenotype, measured both clinically and on MRI...
  39. ncbi request reprint Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction
    R H C Lazeron
    Department of Neurology, Vrije Universiteit Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Mult Scler 12:760-8. 2006
    ..Since MS is characterized by cognitive slowing rather than impaired accuracy, we used the Amsterdam Neuropsychological Tasks (ANT) program, a computerized test proven to be very sensitive to cognitive slowing in MS patients...
  40. ncbi request reprint Optimizing the association between disability and biological markers in MS
    N F Kalkers
    MS MRI Center, VU Medical Center, Amsterdam, The Netherlands
    Neurology 57:1253-8. 2001
    ..The authors studied the relation of brain volume measurements with the MS Functional Composite (MSFC) in an attempt to improve the clinico-radiologic association...
  41. ncbi request reprint Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis
    M J Eikelenboom
    Department of Neurology, VU Medical Centre, De Boelelaan 1117, PO Box 7057, 1007 MB, Amsterdam, The Netherlands
    J Neuroimmunol 133:225-32. 2002
    ..Our results suggest that chemokines may play a more important role in the development of new lesions in MS than in the long-term outcome of those lesions...
  42. doi request reprint Relevance of IL7R genotype and mRNA expression in Dutch patients with multiple sclerosis
    M H Sombekke
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 17:922-30. 2011
    ..Analysis of rs6897932 (the most strongly MS-associated single nucleotide polymorphism (SNP)), showed effects of genotype on the relative expression of membrane-bound to total amount of IL7R mRNA...
  43. ncbi request reprint T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment
    F Barkhof
    MR MS centre, VU Medical Centre, Amsterdam, The Netherlands
    Brain 124:1396-402. 2001
    ..In patients with SP multiple sclerosis, IFNbeta-1b treatment reduces the development of hypointense T(1) lesions, suggesting that reduced axonal damage in lesions may play a part in the beneficial effect that is observed clinically...
  44. pmc Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life
    F A H van der Linden
    Department of Neurology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 77:1157-62. 2006
    ..In these situations proxies may provide valuable information, provided we can be certain that proxies and patients give consistent ratings...
  45. ncbi request reprint Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients
    A Minneboo
    MR Center for MS Research, VU University Medical Center, Amsterdam, The Netherlands
    Neurology 65:56-61. 2005
    ..It is unclear whether the same applies to the evolution of lesions on T1-weighted MRI...
  46. ncbi request reprint Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis: a correlative study with conventional MRI, histopathology and clinical phenotype
    G J Nijeholt
    Dutch MR Center for MS Research, Department of Radiology, Vrije Universiteit Hospital, Amsterdam, The Netherlands
    Brain 124:154-66. 2001
    ..Furthermore, we found very good correlation between the extent of abnormalities shown by histopathology and the SI changes on proton-density MRIs, mainly relating to demyelination revealed histopathologically...
  47. ncbi request reprint MS functional composite: relation to disease phenotype and disability strata
    N F Kalkers
    Department of Neurology, Academisch Ziekenhuis Vrije Universiteit Amsterdam, The Netherlands
    Neurology 54:1233-9. 2000
    ....
  48. doi request reprint Serum homocysteine levels in relation to clinical progression in multiple sclerosis
    C E Teunissen
    Molecular Cell Biology and Immunology, VU University Medical Centre, FdG, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 79:1349-53. 2008
    ..Homocysteine levels may be elevated in patients with multiple sclerosis (MS) but large studies are lacking and the relation with disease progression remains to be determined...
  49. ncbi request reprint Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease
    H Vrenken
    Department of Radiology, MR Center for MS Research, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 13:708-16. 2007
    ..We conclude that disease-induced MTR changes were small in MS NAWM and NAGM, but did correlate with clinical decline, lesion volume and overall cerebral atrophy...
  50. ncbi request reprint Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis
    R H C Lazeron
    MS Center, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Mult Scler 11:524-31. 2005
    ..In conclusion, cognitive impairment in MS is moderately dependent on amount (and distribution) of structural brain damage, especially in the more physically impaired patients group...
  51. doi request reprint Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis
    I J van den Elskamp
    Department of Radiology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Mult Scler 16:660-9. 2010
    ..Recovery of lesion MTR is a feasible outcome measure for future multicentre clinical trials measuring the effect of remyelinating agents...
  52. ncbi request reprint Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination
    J C J Bot
    MR Center for MS Research, Departments of Radiology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Neurology 62:226-33. 2004
    ....
  53. doi request reprint Gender differences in multiple sclerosis: cytokines and vitamin D
    M J Eikelenboom
    Department of Neurology, VU University Medical Center, 1007MB Amsterdam, The Netherlands
    J Neurol Sci 286:40-2. 2009
    ..The immune system is influenced by different factors including hormones and seasonal fluctuations (vitamin D). This overview will highlight the gender differences in MS, with emphasis on the cytokines and vitamin D...
  54. doi request reprint Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis
    P Tewarie
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    J Neuroimmunol 251:103-6. 2012
    ..The role of antimyelin antibodies as biomarker in multiple sclerosis is subject of debate. Here antimyelin antibody reactivity against native myelin is studied in CSF and serum...
  55. doi request reprint Interferon-beta bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice
    L F van der Voort
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 15:212-8. 2009
    ..Unclear is how to apply IFN beta bioactivity measurements (quantification of Myxovirus resistance protein A (MxA) mRNA) in clinical practice...
  56. doi request reprint Community walking can be assessed using a 10-metre timed walk test
    J C E Kempen
    Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 17:980-90. 2011
    ..The second purpose was to determine the Minimally Important Change (MIC) in absolute gait speed using the MFWC and Expanded Disability Status Scale (EDSS) as external criteria...
  57. ncbi request reprint Factor structure of the Disability and Impact Profile in patients with multiple sclerosis
    L Cohen
    Department of Medical Psychology, Vrije Universiteit, Amsterdam, The Netherlands
    Qual Life Res 8:141-50. 1999
    ..The two factors correlate well with instruments measuring disability and with satisfaction versus emotional distress. Provisional scales based on the factors were constructed...
  58. ncbi request reprint Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability
    E L J Hoogervorst
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 10:569-74. 2004
    ....
  59. ncbi request reprint Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy
    N F Kalkers
    Department of Neurology, Academic Hospital Vrije Universiteit, Amsterdam, The Netherlands
    J Neurol Sci 184:155-62. 2001
    ..We studied correlations between MTR histogram and clinical parameters in MS subgroups. Contrary to earlier studies we placed special emphasis on the lower MTR range, to explore the effect of partial volume averaging effects with CSF...
  60. ncbi request reprint Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis
    H Vrenken
    Department of Radiology, MR Center for MS Research, VU University Medical Center, Amsterdam, The Netherlands
    AJNR Am J Neuroradiol 27:2005-11. 2006
    ..We aimed to investigate the relationship of NAWM changes to the distance to the lesions...
  61. doi request reprint Genetic correlations of brain lesion distribution in multiple sclerosis: an exploratory study
    M H Sombekke
    VU University Medical Center, Department of Neurology, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    AJNR Am J Neuroradiol 32:695-703. 2011
    ..We hypothesized that spatial distribution may be partially driven by genetic predisposition, and we aimed to explore relations among candidate genes and the spatial distribution of white matter brain lesions in MS...
  62. ncbi request reprint Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics
    J N P Zwemmer
    Department of Neurology, MS Center, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 12:565-72. 2006
    ..While clinical subtypes differ by magnetic resonance imaging (MRI) signature on a group level, a classification of individual MS patients based purely on MRI characteristics has not been presented so far...
  63. pmc One year changes in disability in multiple sclerosis: neurological examination compared with patient self report
    E L J Hoogervorst
    Department of Neurology, VU Medical Centre, Academisch Ziekenhuis Vrije Universiteit, Postbox 7057, Amsterdam 1007 MB, Netherlands
    J Neurol Neurosurg Psychiatry 74:439-42. 2003
    ....
  64. ncbi request reprint No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis
    J N P Zwemmer
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 10:272-7. 2004
    ..In addition the data were combined with available data from the literature...
  65. pmc The INTERMED: a screening instrument to identify multiple sclerosis patients in need of multidisciplinary treatment
    E L J Hoogervorst
    Department of Neurology, VU Medical Centre, Post boc 7057, 1007 MB Amsterdam, Netherlands
    J Neurol Neurosurg Psychiatry 74:20-4. 2003
    ....
  66. ncbi request reprint Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS
    S C J Huijbregts
    Department of Clinical Neuropsychology, Vrije Universiteit, Amsterdam, The Netherlands
    Neurology 63:335-9. 2004
    ....
  67. doi request reprint The search for responsive clinical endpoints in primary progressive multiple sclerosis
    L V A E Bosma
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 15:715-20. 2009
    ....
  68. ncbi request reprint TNFalpha production by CD4(+) T cells predicts long-term increase in lesion load on MRI in MS
    J Killestein
    Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Neurology 57:1129-31. 2001
    ..A correlation was found between the percentage of tumor necrosis factor-alpha-producing CD4(+) T cells at baseline and the change in T2 lesion load during 3-year follow-up (r = 0.79, adjusted r(2) = 0.59, p = 0.001)...
  69. ncbi request reprint The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite
    E L J Hoogervorst
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 10:55-60. 2004
    ....
  70. ncbi request reprint Sex differences in proinflammatory cytokine profiles of progressive patients in multiple sclerosis
    M J Eikelenboom
    Department of Neurology at the VU Medical Centre, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands
    Mult Scler 11:520-3. 2005
    ..In conclusion, the data presented indicate that cytokine production and sex differences in cytokine production might differ between disease phases, probably related to underlying disease mechanisms...
  71. ncbi request reprint Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta
    J Killestein
    Department of Neurology, VU Medical Center, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    J Neuroimmunol 133:217-24. 2002
    ..Evidence suggests a role of T cell reactivity in autoimmune diseases. Interferon (IFN)-beta blocks in vitro proliferation of human T cells...
  72. ncbi request reprint The usefulness of evaluative outcome measures in patients with multiple sclerosis
    V de Groot
    Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, The Netherlands
    Brain 129:2648-59. 2006
    ..In sum, in the early stages of multiple sclerosis the most useful evaluative outcome measures for research are the SF36pf (physical functioning) and the RAPocc (social functioning)...
  73. doi request reprint Proxy ratings from multiple sources: disagreement on the impact of multiple sclerosis on daily life
    F A H van der Linden
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Neurol 15:933-9. 2008
    ..In these situations proxy respondents, such as close relatives or healthcare providers, may provide valuable information. To examine the accuracy and value of healthcare providers and close relatives to assess disease impact of MS...
  74. ncbi request reprint CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis
    Tineke van Veen
    Department of Neurology, VU University Medical Centre, De Boelelaan 1117, 1007 MB, Amsterdam, The Netherlands
    J Neuroimmunol 140:188-93. 2003
    ..We observed no effects of the polymorphisms on brain and lesion volumes. These data suggest that the polymorphisms under investigation do not affect the risk of developing MS and have no influence on the course of disease...
  75. ncbi request reprint The FAS-670 polymorphism influences susceptibility to multiple sclerosis
    T van Veen
    Department of Neurology, VU Medical Centre, De Boelelaan 1117, 1007 MB, Amsterdam, The Netherlands
    J Neuroimmunol 128:95-100. 2002
    ..We observed similar brain and lesion volumes in carriers and noncarriers of FAS-670*G. These data suggest that FAS-670*G decreases the risk of developing MS, but does not affect the course of disease...
  76. doi request reprint Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis
    Lisa M L van Winsen
    Department of Neurology, MS Centre Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands
    Mult Scler 16:500-2. 2010
    ..The results suggest the existence of a partial glucocorticoid resistance, in a subgroup of multiple sclerosis patients, which may have implications for treatment efficacy...
  77. ncbi request reprint CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis
    Tineke van Veen
    Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
    J Neuroimmunol 190:157-64. 2007
    ..In summary, our multifaceted study supports the notion that polymorphisms in CCL5 and CCR5 modify the course of MS...
  78. ncbi request reprint Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis
    E L Hoogervorst
    Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Mult Scler 7:335-9. 2001
    ..It is obvious from this study that such a treatment can have a differential effect on measurements of functional impairment, rating of neurologic examination and patient self-report...
  79. ncbi request reprint Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: metabolite concentrations, quantification precision, and reproducibility
    Jeroen J G Geurts
    Department of Radiology, MR Center for MS Research, VU University Medical Center, Amsterdam, The Netherlands
    J Magn Reson Imaging 20:366-71. 2004
    ....
  80. ncbi request reprint Current trials in multiple sclerosis: established evidence and future hopes
    Joep Killestein
    Department of Neurology, MS Centre, VU Medical Centre Amsterdam, Amsterdam, The Netherlands
    Curr Opin Neurol 18:253-60. 2005
    ..The aim of the present report is to briefly review multiple sclerosis therapeutic trials published or presented in 2004 to provide an up-to-date overview of the established evidence and new insights...
  81. ncbi request reprint Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels
    Sarah Floris
    Department of Molecular Cell Biology, VU Medical Center, P O Box 7057, 1007 MB, Amsterdam, The Netherlands
    J Neuroimmunol 148:172-7. 2004
    ..Therefore, we conclude that although MRP8/14 expression is a good histopathological marker for monocyte activation, serum levels of these proteins do not correlate with disease activity in RR MS...
  82. doi request reprint Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI
    J J G Geurts
    VU University Medical Center, Department of Anatomy and Neuroscience, MF G 116, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
    Neurology 76:418-24. 2011
    ..This study aimed to formulate consensus recommendations for scoring cortical lesions in patients with MS, using DIR images acquired in 6 European centers according to local protocols...
  83. doi request reprint Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types
    H Vrenken
    Department of Radiology, MS Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
    AJNR Am J Neuroradiol 31:541-8. 2010
    ..This study aimed to characterize DAWM in vivo by using 4 quantitative MR imaging measures and to explore differences between MS disease types...
  84. doi request reprint Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis
    Alexandra Seewann
    Department of Neurology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Arch Neurol 66:601-9. 2009
    ..Underlying pathologic and MRI characteristics of DAWM are largely unknown...
  85. doi request reprint Long-term follow-up of suspected though unconfirmed MS
    J M Nielsen
    Department of Neurology, VU University Medical Center, MS Center, Amsterdam, The Netherlands
    Mult Scler 14:985-7. 2008
    ..We report, after 7 years, on the diagnoses made in a cohort of patients with suspected though unconfirmed MS...
  86. ncbi request reprint Diagnosing MS: recent guidelines and future goals focusing on magnetic resonance imaging
    J M Nielsen
    Department of Neurology, VU Medical Centre, De Boelelaan 1117, 1007 MB Amsterdam, The Netherlands
    Int MS J 14:29-34. 2007
    ..Criteria for PPMS were also revised. Current research is concentrating on the definition of uniform clinical terms, to allow a more standardized diagnosis, and aims to simplify the criteria while improving diagnostic accuracy...
  87. doi request reprint Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis
    L F van der Voort
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Eur J Neurol 16:1049-52. 2009
    ..Although absent IFNbeta bioactivity is associated with NAb and NAb are associated with reduced drug efficacy, the direct relationship between IFNbeta bioactivity and clinical disease activity is largely unknown...
  88. doi request reprint Interferon regulatory factor 5 gene variants and pharmacological and clinical outcome of Interferonβ therapy in multiple sclerosis
    S Vosslamber
    VU University Medical Center, Department of Pathology, Amsterdam, The Netherlands
    Genes Immun 12:466-72. 2011
    ..037). These findings suggest a role for IRF5 gene variation in the pharmacological and clinical outcome of IFNβ therapy that might have relevance as biomarker to predict the response to IFNβ in multiple sclerosis...
  89. ncbi request reprint Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results
    J M Nielsen
    Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 13:717-21. 2007
    ..Recently, a clinical classification system was described to determine whether symptoms and signs of patients presenting with a first episode suggestive of multiple sclerosis (MS) indicate the presence of monofocal or multifocal disease...
  90. ncbi request reprint Motor evoked potential: a reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI
    N F Kalkers
    Department of Neurology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Clin Neurophysiol 118:1332-40. 2007
    ..In an attempt to analyze whether MEP can serve as a valid measure for evaluating neurological dysfunction in multiple sclerosis (MS), we related MEP to clinical and MRI measures...
  91. ncbi request reprint Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis
    C E Teunissen
    Department of Molecular Cell Biology and Immunology, VU University Medical Centre, Amsterdam, The Netherlands
    Neuropathol Appl Neurobiol 32:318-31. 2006
    ..The increased levels of GAP-43 in remyelinated or nondemyelinated white matter close to MS lesions may reflect regenerative attempts by damaged axons...
  92. ncbi request reprint Multiple sclerosis functional composite: impact of reference population and interpretation of changes
    B M J Uitdehaag
    Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
    Mult Scler 8:366-71. 2002
    ....
  93. ncbi request reprint The initial course of daily functioning in multiple sclerosis: a three-year follow-up study
    V de Groot
    Department of Rehabilitation Medicine, VU University Medical Center, Amsterdam, The Netherlands
    Mult Scler 11:713-8. 2005
    ..Patients in the non-relapse onset group have progressive neurological symptoms that are accompanied by progressive limitations in physical functioning, but not by progressive limitations in the other domains...
  94. ncbi request reprint Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions
    E Bergers
    Dutch MR MS Center and Department of Radiology, VU University Medical Center, Amsterdam, The Netherlands
    Neurology 59:1766-71. 2002
    ..To determine the degree of axonal damage in relationship to signal abnormalities on T2-weighted high-resolution MRI in spinal cord tissue of patients with MS...
  95. pmc Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use
    F A H van der Linden
    Department of Neurology, VU University Medical Centre, Amsterdam, Netherlands, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 76:1677-81. 2005
    ..In such cases proxies may provide valuable information. However, before using any questionnaires in a proxy sample, the questionnaire should be evaluated for proxy use...
  96. ncbi request reprint The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study
    N F Kalkers
    Department of Neurology, Magnetic Resonance Centre for Multiple Sclerosis Research, VU Medical Center, PO Box 7057, Amsterdam 1007 MB, The Netherlands
    Mult Scler 8:532-3. 2002
    ..In a run-in versus treatment trial, we show that the neuroprotective agent riluzole seems to reduce the rate of cervical cord atrophy and the development of hypointense T1 brain lesions on magnetic resonance imaging...
  97. ncbi request reprint [Medicinal cannabis for diseases of the nervous system: no convincing evidence of effectiveness]
    J Killestein
    VU Medisch Centrum, Postbus 7057, 1007 MB, Amsterdam
    Ned Tijdschr Geneeskd 148:2374-8. 2004
    ..However, it is also not possible to conclude definitely that cannabinoids are ineffective; still, this is no basis for official stimulation of their use...
  98. ncbi request reprint Value of health-related quality of life to predict disability course in multiple sclerosis
    M A J Visschedijk
    Department of Medical Psychology, VU University Medical Center, Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
    Neurology 63:2046-50. 2004
    ..To determine the value of health-related quality of life (HRQoL) to predict change in disability status in patients with multiple sclerosis (MS)...
  99. ncbi request reprint Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist
    B W van Oosten
    Department of Neurology, VU University Medical Centre, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Mult Scler 10:330-1. 2004
    ..The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabinoid system might indeed be relevant to disease pathogenesis in MS...
  100. ncbi request reprint [New diagnostic criteria for multiple sclerosis in clinical practice]
    B W van Oosten
    VU Medisch Centrum, Amsterdam
    Ned Tijdschr Geneeskd 148:1417-22. 2004
    ..He had a vasculopathy. The second woman had dissemination in time and place, but there was a better explanation for the symptoms: neuromyelitis optica...
  101. ncbi request reprint Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone
    E L J Hoogervorst
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 8:415-9. 2002
    ..Multiple sderosis (MS) patients develop varying degrees of cerebral atrophy, which may already begin at disease onset The purpose of this study is to examine the effect of steroid treatment on cerebral volume in MS patients...